The concentrations of per- and polyfluoroalkyl substances (PFASs) in the Finnish aquatic environment were measured in riverine waters and in inland, coastal and open sea fish. In addition, the PFAS load to the Baltic Sea from 11 rivers was calculated. Measurements show that PFASs, including restricted perfluorooctane sulfonic acid (PFOS), are widely present in the Finnish aquatic environment. At three out of 45 sampling sites, the concentration of PFOS in fish exceeded the environmental quality standard (EQS) of the Water Framework Directive (WFD). The annual average (AA) ∑23PFAS concentration in surface waters ranged from 1.8 to 42 ng L−1 and the concentration of PFOS exceeded the AA-EQS in three out of 13 water bodies. In European perch (Perca fluviatilis) and Baltic herring (Clupea harengus membras), the ∑PFAS concentration ranged from 0.98 to 1 µg kg−1 f.w. (fresh weight) and from 0.2 to 2.4 µg kg−1 f.w., respectively. The highest concentrations in both surface water and fish were found in waters of southern Finland. The riverine export of ∑10PFAS to the Baltic Sea from individual rivers ranged from 0.4 kg yr−1 to 18 kg yr−1. PFAS concentrations in fish of point-source-polluted sites and coastal sites were higher compared to fish of open sea or diffusely polluted sites. The PFAS profiles in surface waters of background sites were different from other sites. This study shows that PFASs are widely found in the Finnish aquatic environment. Different PFAS profiles in samples from background areas and densely populated areas indicate diverse sources of PFASs. Although atmospheric deposition has a substantial influence on PFAS occurrence in remote areas, it is not the dominant source of all PFASs to the aquatic environment of Finland. Rather, wastewaters and presumably contaminated land areas are major sources of PFASs to this aquatic environment.
Leverett et al. commented on the Environmental quality standard (EQS) for diclofenac derived under the European Water Framework Directive [Leverett et al. (2021) Environ Sci Eur 33: 133 https://doi.org/10.1186/s12302-021-00574-z]. They postulated that the derivation of the EQS value for diclofenac is not conducted according to the EQS Technical Guidance, but rather using data of poor reliability and relevance. Consequently, the authors suggested using their alternative derived value instead. It is to be noted that the process for the EQS derivation for diclofenac is still ongoing and not finalized, and that as a consequence, any critical analysis is very premature. In general, within the current European Commission process, EQS values proposals are derived by expert groups led by the Joint Research Centre. In the specific case for diclofenac, Leverett et al. have also been actively involved as experts. This response to Leverett et al. (2021) aims to clarify the reasoning behind the proposal from a scientific point of view and to express our concern for the lack of transparency of their position in the statement of competing interests. Indeed, the authors did not disclose their participation in the expert group for deriving the diclofenac EQS value, nor that they have direct and indirect ties to a company that markets diclofenac in Europe, Glaxo Smith & Kline plc (GSK). This amounts to a significant conflict of interest and leads to disinformation to the reader.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.